Subscribe To

Price Alert Latest News Economic Calendar News

ARFXF / ProMIS Neurosciences submits IND application for Alzheimer's treatment

ProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's disease (AD). The development stage biotechnology company explained that PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta that are believed to be a major driver of AD, as opposed to monomers or plaque. Read More

Demo Live Account See Partner Details

Content Topics

Promis

Neurosciences

Submits

Application

Alzheimer

Alzheimer s

Treatment

Stock

ARFXF

Posted: Apr 10 2023, 09:11

Author Name: Proactive Investors

ARFXF News

By Proactive Investors
April 10, 2023

ProMIS Neurosciences submits IND application for Alzheimer's treatment

ProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (

By Pulse2
July 9, 2022

ProMIS Neurosciences (PMN) Stock Surged 32.33% In Nasdaq Debut: Details

The shares of ProMIS Neurosciences Inc. (Nasdaq: PMN) surged 32.33% in its Nasdaq debut. These are some details you should know.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.